JP2020520359A5 - - Google Patents

Download PDF

Info

Publication number
JP2020520359A5
JP2020520359A5 JP2019563494A JP2019563494A JP2020520359A5 JP 2020520359 A5 JP2020520359 A5 JP 2020520359A5 JP 2019563494 A JP2019563494 A JP 2019563494A JP 2019563494 A JP2019563494 A JP 2019563494A JP 2020520359 A5 JP2020520359 A5 JP 2020520359A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
cancer
compound according
ethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019563494A
Other languages
English (en)
Japanese (ja)
Other versions
JP7065117B2 (ja
JP2020520359A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/062865 external-priority patent/WO2018210995A1/en
Publication of JP2020520359A publication Critical patent/JP2020520359A/ja
Publication of JP2020520359A5 publication Critical patent/JP2020520359A5/ja
Application granted granted Critical
Publication of JP7065117B2 publication Critical patent/JP7065117B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019563494A 2017-05-18 2018-05-17 N-置換インドール誘導体 Expired - Fee Related JP7065117B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/062008 2017-05-18
EP2017062008 2017-05-18
PCT/EP2018/062865 WO2018210995A1 (en) 2017-05-18 2018-05-17 N-substituted indole derivatives

Publications (3)

Publication Number Publication Date
JP2020520359A JP2020520359A (ja) 2020-07-09
JP2020520359A5 true JP2020520359A5 (https=) 2021-07-26
JP7065117B2 JP7065117B2 (ja) 2022-05-11

Family

ID=62186481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563494A Expired - Fee Related JP7065117B2 (ja) 2017-05-18 2018-05-17 N-置換インドール誘導体

Country Status (32)

Country Link
US (2) US20200069686A1 (https=)
EP (1) EP3625224B1 (https=)
JP (1) JP7065117B2 (https=)
KR (1) KR102650756B1 (https=)
CN (1) CN110621666A (https=)
AR (1) AR111806A1 (https=)
AU (1) AU2018269667B2 (https=)
BR (1) BR112019024114A2 (https=)
CA (1) CA3063637A1 (https=)
CL (1) CL2019003257A1 (https=)
CO (1) CO2019010804A2 (https=)
CR (1) CR20190567A (https=)
CY (1) CY1124528T1 (https=)
DK (1) DK3625224T3 (https=)
EA (1) EA039630B1 (https=)
ES (1) ES2894124T3 (https=)
HR (1) HRP20211532T1 (https=)
HU (1) HUE056406T2 (https=)
IL (1) IL270616B (https=)
LT (1) LT3625224T (https=)
MA (1) MA49127B1 (https=)
MX (1) MX394108B (https=)
PE (1) PE20191787A1 (https=)
PH (1) PH12019502562B1 (https=)
PL (1) PL3625224T3 (https=)
PT (1) PT3625224T (https=)
RS (1) RS62441B1 (https=)
SG (1) SG11201908660RA (https=)
SI (1) SI3625224T1 (https=)
TW (1) TWI768043B (https=)
UA (1) UA124748C2 (https=)
WO (1) WO2018210995A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
US11839613B2 (en) 2017-05-18 2023-12-12 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
PE20191814A1 (es) 2017-05-18 2019-12-27 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
TW201900179A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
WO2021060281A1 (ja) * 2019-09-24 2021-04-01 Agc株式会社 プロスタグランジンe2レセプターep2/ep4デュアルアンタゴニスト
CN115697317A (zh) * 2020-04-08 2023-02-03 株式会社AskAt Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2402099C (en) 2000-03-24 2011-04-26 Pharmagene Laboratories Ltd. Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
AU2003216579A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Imidazole compounds as anti-inflammatory and analgesic agents
AU2003216581A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
CN1662551A (zh) 2002-05-23 2005-08-31 瑟瑞技术公司 前列腺素e2受体亚型ep4的拮抗肽
DE602004013938D1 (de) 2003-01-29 2008-07-03 Asterand Uk Ltd Hemmstoffe des ep4-rezeptors
RU2358975C2 (ru) * 2003-08-26 2009-06-20 Тейдзин Фарма Лимитед Пирролопиримидиноновые производные
KR100747401B1 (ko) 2003-09-03 2007-08-08 화이자 인코포레이티드 프로스타글란딘 e2 길항제로서의 페닐 또는 피리딜 아미드 화합물
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
MXPA06011555A (es) 2004-05-04 2006-12-15 Pfizer Compuestos de metil-aril o heteroaril-amida sustituida.
JP4054369B2 (ja) 2004-05-04 2008-02-27 ファイザー株式会社 オルト置換アリールまたはヘテロアリールアミド化合物
GT200500284A (es) 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
WO2006122403A1 (en) 2005-05-19 2006-11-23 Merck Frosst Canada Ltd. Quinoline derivatives as ep4 antagonists
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
ES2392192T3 (es) 2006-04-24 2012-12-05 Merck Canada Inc. Derivados de indol amida como antagonistas del receptor EP4
WO2007143825A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
PL2044056T3 (pl) 2006-07-14 2013-01-31 Novartis Ag Pochodne pirymidyny jako inhibitory ALK-5
US8969394B2 (en) 2006-08-11 2015-03-03 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as EP4 receptor ligands
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
CA2679175C (en) 2007-02-26 2015-01-13 Merck Frosst Canada Ltd. Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
CN101636385B (zh) 2007-03-26 2012-09-05 默克弗罗斯特加拿大有限公司 作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物
US8030489B2 (en) 2007-03-26 2011-10-04 Astellas Pharma Inc. Ornithine derivative
EP2014657A1 (de) 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
JP5408434B2 (ja) 2007-07-03 2014-02-05 アステラス製薬株式会社 アミド化合物
EP2565191B1 (en) 2008-05-14 2014-10-08 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
JP5536773B2 (ja) 2008-08-14 2014-07-02 ベータ・ファーマ・カナダ・インコーポレイテッド Ep4受容体アンタゴニストとしてのヘテロ環式アミド誘導体
WO2010032123A1 (en) 2008-09-19 2010-03-25 Biotechnology Research Corporation Limited Triterpenoid compounds and methods of use thereof
WO2010034110A1 (en) 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
PE20131343A1 (es) 2010-09-21 2013-11-18 Eisai Randd Man Co Ltd Derivados de acido benzoico
NZ609887A (en) 2010-09-29 2015-01-30 Nb Health Lab Co Ltd Antibody against human prostaglandin e2 receptor ep4
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
DK2688883T3 (en) * 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
DK2729445T3 (en) 2011-07-04 2016-01-18 Rottapharm Biotech Srl CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
MX371331B (es) 2012-04-24 2020-01-27 Vertex Pharma Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
JO3296B1 (ar) 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基-苯甲酸化合物
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
CA2914997C (en) 2013-06-12 2021-07-20 Kaken Pharmaceutical Co., Ltd. 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
CN105705489B (zh) 2013-09-04 2019-04-26 百时美施贵宝公司 用作免疫调节剂的化合物
HUE038169T2 (hu) 2013-09-06 2018-09-28 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazol származékok mint immunomodulátorok
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
HRP20180804T1 (hr) 2013-10-17 2018-08-10 Vertex Pharmaceuticals Incorporated Inhibitori dnk-pk
ME03398B (me) 2013-12-17 2020-01-20 Lilly Co Eli Spojevi dimetilbenzojeve kiseline
ME02896B (me) 2013-12-17 2018-04-20 Lilly Co Eli Fenoksietilni derivati prstenastog amina i njihova aktivnost kao modulatora receptora ep4
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ep4配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
AU2015264102C1 (en) 2014-05-23 2020-10-08 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
WO2016054807A1 (en) 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
TWI852872B (zh) 2015-01-09 2024-08-11 日商小野藥品工業股份有限公司 三環性螺化合物之用途
EP3325490B1 (en) 2015-07-23 2019-12-18 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
BR112018007664B1 (pt) 2015-10-16 2023-12-19 Eisai R&D Management Co., Ltd Compostos antagonistas de ep4, composição compreendendo o composto e uso dos mesmos para tratar câncer

Similar Documents

Publication Publication Date Title
JP2020520359A5 (https=)
JP2022541483A5 (https=)
JP2018513107A5 (https=)
JP2023512175A5 (https=)
JP2019059760A5 (https=)
JP2023512174A5 (https=)
JP6854386B2 (ja) リゾホスファチジン酸受容体1(lpar1)阻害剤化合物
HRP20211532T1 (hr) N-supstituirani derivati indola
JP2020507589A5 (https=)
JP2018048154A5 (https=)
JP2017528507A5 (https=)
JP2014526501A5 (https=)
JP2016528301A5 (https=)
JP2020533352A5 (https=)
CN1444478A (zh) 塞利克西组合物在快速缓解疼痛中的用途
JP2006526590A5 (https=)
JP2015524444A5 (https=)
JP2016534063A5 (https=)
JP2020532547A5 (https=)
JP2006517939A5 (https=)
JP2014516942A5 (https=)
JP2015510916A5 (https=)
JP2019520344A5 (https=)
JP2015522018A5 (https=)
JP2015507004A5 (https=)